Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
New Managers July 2013

Profiles: The Ogee Structured Opportunities Fund; the Shaked Opportunity fund of hedge funds.

Tail risk is the best place for Ogee Structured Fund at this time

Komfie Manalo, Opalesque Asia for New Managers:

Sebastien Bossu

Sebastien Bossu, principal at New York-based hedge fund firm Ogee Group, which manages the Ogee Structured Opportunities, Ltd., is working to launch several alpha-generating strategies, such as volatility and correlation arbitrage. But in the meantime, he feels that tail risk is the best place for his firm to be. "Our fund's strategy is to invest the capital in lower-risk securities such as investment-grade bonds (the beta layer) while selling tail risk on select underlying assets using equity derivatives (the alpha layer)," he says in an interview with Opalesque.

The Ogee Structured Opportunities Fund is currently featured in Opalesque Solutions' Emerging Managers Database.

Read the full article here: http://www.opalesque.com/647216/Tail_risk_is_the_best_place_for_Ogee721.html

 

Shaked Capital Advisors performs well with strongest tail winds for long and head winds for short exposure

Komfie Manalo, Opalesque Asia for New Managers:

Amir Shaked

Shaked Capital Advisors is enjoying strong returns despite volatilities in the markets and the sell off last June, says Managing Partner Amir Shaked. The asset manager runs the fund of hedge funds Shaked Opportunity Fund, which is currently featured in Opalesque Solutions' Emerging Managers Database.

"The fund is perf......................

To view our full article please login

This article was published in Opalesque's New Managers a top-down monthly analysis, news and research publication on the global emerging manager space.
New Managers
New Managers
New Managers

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for